Experienced in Peripheral T-Cell Lymphoma

Rena J. Buckstein

Toronto, ON, CA 
Experienced in Peripheral T-Cell Lymphoma
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Rena Buckstein practices in Toronto, Canada. Ms. Buckstein is rated as an Experienced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Follicular Lymphoma, Chronic Myelomonocytic Leukemia (CMML), Leukemia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 122 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Peripheral T-Cell Lymphoma.

Gender
Female

Locations

Toronto, ON, Canada
Other Locations
Toronto, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
A PHASE II STUDY OF Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)
A PHASE II STUDY OF Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)
Enrollment Status: Terminated
Publish Date: April 26, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

122 Total Publications

Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?
Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?
Journal: Haematologica
Published: June 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Buckstein's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile